Clinical Trial Detail

NCT ID NCT03654716
Title Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

rhabdoid cancer

hepatoblastoma

retinoblastoma

lymphoma

Advanced Solid Tumor

Therapies

ALRN-6924 + Cytarabine

ALRN-6924

Age Groups: adult child

Additional content available in CKB BOOST